Stellest®
essilor

Discover why they're right for your child



Essilor® Stellest® lenses represent Essilor's breakthrough* innovation in myopia management— the first and only FDA market authorized spectacle lens to slow the progression of myopia in children†1.

Essilor® Stellest® lenses:

Correct myopia with single vision zone to ensure sharp vision

Slowed myopia progression by 71% on average†1

An easy to use and proven†1 way to help manage your child's myopia

Discover Essilor® Stellest® lenses



essilor evolving vision

Let's connect

*The U.S. Food and Drug Administration (FDA) granted Breakthrough Device designation to the Essilor® Stellest® spectacle lens in April 2021.

†Compared to single vision lenses. Results from a prospective, randomized, double-masked, multicenter U.S. clinical trial in myopic children aged 6–12 years at initiation of treatment.

1.Essilor International, data on file (2025